Tennessee House Bill HB0801

Tennessee 2023-2024 Regular Session

• Introduced: 1/30/23
• Refer: 2/2/23
• Refer: 2/21/23
• Refer: 2/28/23
• Refer: 3/8/23
• Refer: 3/14/23
• Chaptered: 4/25/23
• Passed: 4/25/23

Caption

AN ACT to amend Tennessee Code Annotated, Title 56, Chapter 7, Part 23, relative to the Proton Therapy Access Act.

Impact

The implications of HB 0801 are significant for the treatment of cancer patients in Tennessee. By mandating that insurance coverage aligns with that of IMRT, the bill is likely to improve access to proton therapy for eligible patients, potentially leading to better health outcomes. The financial alignment with IMRT payments seeks to eliminate any cost barriers that might prevent patients from accessing this advanced treatment modality, thereby promoting equitable healthcare access. Additionally, the bill signals a legislative recognition of the importance of innovative treatment options in cancer care.

Summary

House Bill 0801 establishes the Proton Therapy Access Act, which amends the Tennessee Code to facilitate coverage for hypofractionated proton therapy under state group insurance programs. This bill aims to ensure patients diagnosed with certain types of cancer can receive proton therapy, a specialized form of radiation treatment, at an equivalent cost to standard intensity-modulated radiation therapy (IMRT). The legislation stipulates that coverage should be granted to patients participating in clinical trials or registries, provided they meet specific criteria outlined in the bill, ensuring high standards in treatment provision.

Sentiment

General sentiment surrounding HB 0801 appears to be supportive, particularly among advocates for cancer treatment accessibility. Legislators expressed a commitment to improving healthcare for cancer patients, underscoring the bill's potential to benefit those requiring advanced treatment. However, there may be concerns from stakeholders regarding the adequacy of coverage and the administrative burden that could arise from implementing the provisions set forth in the bill.

Contention

While the bill is largely viewed favorably, it does face some contention particularly around the details of implementation. Some critics may point to how effectively the insurance providers will adapt to cover the new treatment adequately and in a timely manner. Furthermore, there might be concerns about whether the standards for 'eligible patients' are strict enough to guarantee the highest quality treatments, prompting discussions regarding the rigorousness of the protocols outlined within the bill. Nonetheless, the act signifies an important step forward in enhancing cancer treatment protocols within the state.